Osteoarthritis today: Lost in translation?
Osteoarthritis today: Lost in translation?
复制标题
DOI：
10.1016/j.berh.2022.101810
复制
发表时间：
2022-12-01
期刊：
影响因子：
--
通讯作者：
Lane, Nancy E
中科院分区：
文献类型：
--
作者：
Kennedy, Sarah;Tambiah, Jeyanesh R S;Lane, Nancy E
骨关节炎（OA）是一种非常普遍的关节疾病，与疼痛、功能丧失和高直接和间接经济成本相关。目前的治疗选择是不够的，只能提供适度的症状缓解，没有疾病改变的可能性。虽然许多复杂疾病的治疗选择和个性化药物正在增加，但OA药物的开发一直受到诊断和干预时疾病的晚期状态，症状和进展速度的异质性以及缺乏有效的生物标志物和相关结果测量的阻碍。这篇综述文章总结了OA的现状，包括正在开发的潜在OA治疗方法，美国食品和药物管理局正在评估的潜在生物标志物，以及当前OA治疗指南的总结，特别关注膝关节OA。
Osteoarthritis (OA) is a highly prevalent joint disease that is associated with pain, loss of function, and high direct and indirect economic costs. The current therapeutic options are inadequate, providing only a moderate symptom relief without the possibility of disease modification. While treatment options and personalized medicines are increasing for many complex diseases, OA drug development has been impeded by the advanced state of disease at the time of diagnosis and intervention, heterogeneity in both symptoms and rates of progression, and a lack of validated biomarkers and relevant outcome measures. This review article summarizes the OA landscape, including therapies in development as potential OA treatments, potential biomarkers undergoing evaluation by the US Food and Drug Administration, and a summary of current OA treatment guidelines, with a particular focus on the knee OA.